Top

International Journal of Clinical Oncology

Published in:

01-06-2018 | Original Article

Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy

Published in: International Journal of Clinical Oncology | Issue 3/2018

Abstract

Background

The aim of the present study was to evaluate the prognostic significance of the Glasgow Prognostic Score (GPS) in metastatic renal cell carcinoma (mRCC) patients treated by cytoreductive nephrectomy (CN), and the accuracy of the GPS as a prognostic factor.

Methods

We retrospectively analyzed the data of patients who underwent CN for mRCC between March 1984 and August 2015. In accordance with the GPS criteria, the patients were classified into three groups: GPS 0: C-reactive protein (CRP) ≤ 1.0 mg/dl and albumin ≥ 3.5 g/dl; GPS 1: CRP > 1.0 mg/dl or albumin < 3.5 g/dl; and GPS 2: CRP > 1.0 mg/dl and albumin < 3.5 g/dl.

Results

We enrolled 170 patients (72% male; median age 63.5 years). Fifty-six (33%), 67 (39%), and 47 (28%) patients had a GPS of 0, 1, and 2, respectively. The median overall survivals after CN were 52.4, 19.1, and 8.9 months for patients with a GPS of 0, 1, and 2, respectively (P < 0.0001). In addition to the GPS, Eastern Cooperative Oncology Group performance status (ECOG-PS), Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis were included in the Cox hazards regression model. Multivariate analysis of these factors revealed that the GPS was an independent prognostic factor of overall survival (P < 0.0001). Harrell’s concordance index in the multivariate prognostic model based on ECOG-PS, MSKCC risk criteria, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis was 0.609, which increased to 0.652 after the inclusion of the GPS.

Conclusions

GPS represents an independent prognostic factor for patients who undergo CN for mRCC.

Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659CrossRefPubMed

Mickisch GHJ, Garin A, van Poppel H et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. https://doi.org/10.1016/s0140-6736(01)06103-7 PubMedCrossRef

Flanigan RC, Mickisch G, Sylvester R et al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. https://doi.org/10.1097/01.ju.0000110610.61545.ae CrossRefPubMed

Choueiri TK, Xie W, Kollmannsberger C et al (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. https://doi.org/10.1016/j.juro.2010.09.012 CrossRefPubMed

Heng DY, Wells JC, Rini BI et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. https://doi.org/10.1016/j.eururo.2014.05.034 PubMedCentralCrossRefPubMed

Mathieu R, Pignot G, Ingles A et al (2015) Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol. https://doi.org/10.1016/j.urolonc.2015.05.014 CrossRefPubMed

Petrelli F, Coinu A, Vavassori I et al (2016) Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2016.04.001 PubMedCrossRef

You D, Jeong IG, Ahn JH et al (2011) The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. https://doi.org/10.1016/j.juro.2010.09.018 CrossRefPubMed

Culp SH, Tannir NM, Abel EJ et al (2010) Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. https://doi.org/10.1002/cncr.25046 CrossRefPubMed

10.

Richey SL, Culp SH, Jonasch E et al (2011) Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol Off J Eur Soc Med Oncol ESMO. https://doi.org/10.1093/annonc/mdq563 CrossRef

11.

Margulis V, Shariat SF, Rapoport Y et al (2013) Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. https://doi.org/10.1016/j.eururo.2012.11.040 CrossRefPubMed

12.

Powles T, Blank C, Chowdhury S et al (2011) The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol. https://doi.org/10.1016/j.eururo.2011.05.028 CrossRefPubMed

13.

Debra J, Thomas EH, Charles LC et al (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on heamodialysis. BJU Int 108(8):1279–1283CrossRef

14.

McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. https://doi.org/10.1017/s0029665108007131 PubMedCrossRef

15.

McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. https://doi.org/10.1016/j.ctrv.2012.08.003 CrossRefPubMed

16.

Ramsey S, Lamb GW, Aitchison M et al (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. https://doi.org/10.1002/cncr.22400 CrossRefPubMed

17.

Lamb GW, Aitchison M, Ramsey S et al (2012) Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. https://doi.org/10.1038/bjc.2011.556 PubMedCentralCrossRefPubMed

18.

Sobin LH, Gospodarowicz M, Wittekind CH (2009) Kidney (ICD-O C64). TNM classification of malignant tumors, 7th edn. Wiley-Liss, New York, pp 255–257

19.

Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. https://doi.org/10.1016/j.eururo.2016.02.029 CrossRefPubMed

20.

Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. https://doi.org/10.1200/jco.2002.20.1.289 CrossRef

21.

Harrell FE Jr, Califf RM, Pryor DB et al (1982) Evaluating the yield of medical tests. JAMA 247(18):2543–2546CrossRefPubMed

22.

Ohno Y, Nakashima J, Ohori M et al (2014) Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol. https://doi.org/10.1007/s10147-012-0514-5 CrossRefPubMed

23.

Mekhail TM, Abou-Jawde RM, Boumerhi G et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. https://doi.org/10.1200/JCO.2005.05.179 CrossRef

24.

Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(12)70559-4 PubMedPubMedCentralCrossRef

25.

Saito K, Tatokoro M, Fujii Y et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol. https://doi.org/10.1016/j.eururo.2008.10.012 CrossRefPubMed

26.

Ito H, Shioi K, Murakami T et al (2012) C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer. https://doi.org/10.1186/1471-2407-12-337 CrossRefPubMedPubMedCentral

27.

Koo AS, Armstrong C, Bochner B et al (1992) Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother CII 35(2):97–105CrossRefPubMed

28.

Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250(2):607–610CrossRefPubMed

29.

Gauldie J, Richards C, Harnish D et al (1987) Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84(20):7251–7255CrossRefPubMedPubMedCentral

30.

McMillan DC, Watson WS, O’Gorman P et al (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. https://doi.org/10.1207/S15327914nc392_8 CrossRefPubMed

31.

Day D, Kanjanapan Y, Kwan E et al (2016) Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma. Intern Med J. https://doi.org/10.1111/imj.13202 CrossRefPubMed

32.

Keizman D, Ish-Shalom M, Huang P et al (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. https://doi.org/10.1016/j.ejca.2011.09.001 CrossRefPubMed

33.

Gu L, Ma X, Wang L et al (2016) Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma and construction of a predictive model. Oncotarget. https://doi.org/10.18632/oncotarget.10626 CrossRefPubMedPubMedCentral

34.

Sakai I, Miyake H, Hinata N et al (2013) Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. Int J Clin Oncol. https://doi.org/10.1007/s10147-013-0612-z CrossRefPubMed

Title: Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy
Publication date: 01-06-2018
Published in: International Journal of Clinical Oncology / Issue 3/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1221-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus

The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations

A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma

Time has come for proton and carbon beam therapy

Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy

Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate

Keynote webinar | Spotlight on antibody–drug conjugates in cancer